OMERS ADMINISTRATION Corp Makes New Investment in Guardant Health, Inc. (NASDAQ:GH)

OMERS ADMINISTRATION Corp acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 20,800 shares of the company’s stock, valued at approximately $635,000.

Other hedge funds also recently modified their holdings of the company. R Squared Ltd acquired a new stake in Guardant Health in the fourth quarter worth $26,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health during the fourth quarter valued at about $43,000. Kimelman & Baird LLC bought a new position in shares of Guardant Health during the 4th quarter worth about $58,000. NewEdge Advisors LLC grew its stake in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after buying an additional 230 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Guardant Health in the 4th quarter valued at about $80,000. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on GH. Raymond James reissued an “outperform” rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Piper Sandler reissued an “overweight” rating and issued a $60.00 price target (up previously from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Stifel Nicolaus boosted their price target on shares of Guardant Health from $53.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Barclays upped their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, May 1st. Finally, Scotiabank reiterated an “outperform” rating on shares of Guardant Health in a report on Monday, May 5th. Twenty-one research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Buy” and a consensus target price of $52.32.

Guardant Health Trading Up 0.5%

Shares of Guardant Health stock opened at $40.67 on Monday. The business’s fifty day simple moving average is $43.81 and its 200 day simple moving average is $39.76. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92. The firm has a market capitalization of $5.04 billion, a P/E ratio of -11.42 and a beta of 1.49.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.08. The company had revenue of $203.47 million for the quarter, compared to analysts’ expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.46) EPS. Analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling at Guardant Health

In related news, CEO Amirali Talasaz sold 106,784 shares of the business’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the sale, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 107,132 shares of company stock worth $5,249,355 over the last three months. 6.10% of the stock is currently owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.